| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.031 | 0.3 |
| mRNA | AP-24534 | FIMM | pan-cancer | AAC | -0.17 | 0.3 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | Mitomycin-C | GDSC1000 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.032 | 0.3 |